Physician profile
James Salik
NPI 1740204445
$11,039.83
in general payments reported to CMS, 2019-2025
37 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $402 · 2021: $1,258 · 2022: $2,573 · 2023: $3,814 · 2024: $2,316 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,244 · Education: $14.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,244.44 |
| Education | $14.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,937.13 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,024.13 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $1,005.69 | 2019-2025 | |
| Celgene Corporation | $650.83 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $576.19 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $505.41 | 2019-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $487.53 | 2019-2024 | Stelara |
| Merck Sharp & Dohme LLC | $333.37 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $315.52 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $256.20 | 2020-2023 | Clenpiq, Rebyota |
| Genzyme Corporation | $253.16 | 2022-2024 | |
| Daiichi Sankyo INC. | $194.84 | 2022-2024 | Injectafer |
| Braintree Laboratories, INC. | $184.21 | 2021-2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $155.34 | 2023-2024 | Voquezna |
| Redhill Biopharma INC. | $150.22 | 2020-2024 | Talicia, Movantik, Aemcolo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $118.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.22 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $89.57 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $85.54 | 2023-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $77.31 | 2021-2024 | Linzess |
| Lilly USA, LLC | $69.46 | 2023-2024 | Omvoh |
| Emd Serono, INC. | $68.86 | 2022 | |
| Capsovision, INC. | $65.98 | 2023-2024 | Capsocam Plus |
| Organon LLC | $50.04 | 2023 | Renflexis, Hadlima |
| Romark Laboratories, Lc | $42.87 | 2019 | |
| Laborie Medical Technologies Corp. | $36.95 | 2023 | |
| Phadia US INC. | $34.55 | 2019-2022 | |
| Novo Nordisk INC | $29.86 | 2025 | Wegovy |
| Sandoz INC. | $25.68 | 2023 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $21.45 | 2023 | |
| Vivus LLC | $15.64 | 2024 | Qsymia |
| Celltrion USA INC. | $14.81 | 2024 | Zymfentra |
| Idorsia Pharmaceuticals US INC | $14.71 | 2023 | Quviviq |
| Ucb, INC. | $14.07 | 2019 | |
| Aimmune Therapeutics, INC. | $13.47 | 2024 | |
| Currax Pharmaceuticals LLC | $12.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Salik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.